US4233121A - Process for the preparation of 5-halo-6,9 α-oxido-prostaglandin derivatives - Google Patents
Process for the preparation of 5-halo-6,9 α-oxido-prostaglandin derivatives Download PDFInfo
- Publication number
- US4233121A US4233121A US06/041,104 US4110479A US4233121A US 4233121 A US4233121 A US 4233121A US 4110479 A US4110479 A US 4110479A US 4233121 A US4233121 A US 4233121A
- Authority
- US
- United States
- Prior art keywords
- hydroxyl
- hydrogen
- formula
- electrochemical oxidation
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a new electro-chemical process for the preparation of 5-halo-6,9 ⁇ -oxido-prostaglandin derivatives of the formula II ##STR3## wherein R 1 is hydrogen alkyl which can be substituted by aryl, amino, hydroxyl or halogen an equivalent of a pharmaceutically acceptable organic or inorganic cation or a conventional hydroxyl protecting group;
- R 2 is hydrogen, a hydroxyl group or a conventionally protected hydroxyl group
- R 3 is hydrogen atom or lower alkyl group
- R 4 is hydrogen or conventional hydroxyl protecting group
- R 5 is straight or branched chain alkyl which can contain one or more heteroatoms or be substituted with a substituted or unsubstituted aryl group, and
- X is halogen
- compounds of the formula II are prepared by subjecting prostaglandin F 2 ⁇ derivatives of the formuala I ##STR4## to electro chemical oxidation in a halide ion-containing medium.
- alkyl is intended to include both straight and branched chained hydrocarbons having from 1 to 20 carbon atoms.
- the preferred R 1 alkyl groups contain from 1 to 4 or from 8 to 10 carbon atoms.
- the lower carbon chain facilitates an optional isolation following the reaction, while the longer carbon chain is advantageous because the metabolysis of those prostacyclin derivatives of the formula III ##STR5## prepared by the dehydrohalogenation of 5-halo-6,9 ⁇ -oxido-prostaglandin derivatives of the formula II, which have a longer R 1 alkyl chain is slower.
- R 5 represents an unsubstituted alkyl group, the alkyl chain preferably contains five carbon atoms.
- the lower alkyl groups contain from 1 to 4 carbon atoms.
- Preferred representatives of lower alkyls are methyl, ethyl, n- and isopropyl, and n-, iso-, sec.- and tertiary butyl groups.
- the pharmaceutically acceptable organic and inorganic cations include cations which are not toxic in doses in which prostacyclins are generally administered.
- Preferred inorganic cations include alkali metal and alkaline-earth metal cations, but R 1 can stand also for an equivalent of aluminum, iron or any other non-toxic cation.
- Preferred organic cations include cations derived from various primary, secondary or tertiary alkylamines, arylamines or aralkylamines and from heterocyclic amines. The solubility and crystallizability of the compounds of the formula II, are considerably increased when said cations are substituted, for example by hydroxyl groups.
- hydroxyl protecting groups all groups conventionally used for this purpose in the chemistry of prostaglandins can be used. Typical representatives are: tetrahydropyranyl, various alkylsilyl, aromatic and aliphatic acyl or aromatic carbamoyl groups.
- the protecting groups, if any, can be eliminated after the electro chemical oxidation, for example by hydrolysis.
- 5-halo-6,9 ⁇ -oxido-prostaglandin derivatives of the general formula II are valuable intermediates in the synthesis of prostacyclin derivatives of the general formula III
- R 2 , R 3 , R 4 and R 5 are as defined above, which have anti-coagulant activity.
- prostaglandin F 2 ⁇ or a derivative thereof is reacted with a suitable electrophillic reactant to prepare a corresponding 6,9 ⁇ -oxido-prostaglandin derivative of the formula II, which can subsequently be transformed into a corresponding prostacyclin derivative.
- prostaglandin F 2 ⁇ derivatives of the formula I can be converted into the corresponding 5-halo-6,9 ⁇ -oxido-prostaglandin derivatives of the formula II by electro chemical oxidation, in a medium which contains halide ions, without using any chemical oxidant.
- the electro chemical oxidation is easy to control, and the reaction proceeds quickly and much easier than earlier methods known for this purpose.
- a further advantage of the electro chemical process according to the invention is that it can easily be carried out continuously, in suitably chosen electrolytic cell, and therefore is suitable for a large-scale application.
- a further advantage consists in the fact that the reaction can be regulated by electrical parameters, which can be measured directly, with high accuracy.
- Prostaglandin F 2 ⁇ derivatives of the formula I, used as starting compounds in the reaction according to the invention are known in the art, and are widely used in human and veterinary therapy, primarily for the treatment of female patients.
- Electro chemical halogenation according to the invention is performed in a medium containing halide ions.
- Halide ions are introduced into the electrolyte in the form of suitable salts.
- halides are used which are soluble in the reaction medium.
- Preferred representatives of these halides are alkali metal and alkali-earth metal iodides and bromides but iodide and bromide salts of organic cations can also be used. Due to their good availability and other advantageous properties especially alkali metal iodides and bromides, e.g. sodium, potassium and lithium iodides and bromides are advantageously used for this purpose. Since these salts are readily soluble in the reaction mixture and dissociate therein, they also play the role of a so-called "conducting salt".
- the reaction mixture is neutral or slightly acidic.
- a solvent protic and aprotic polar solvents or mixtures thereof can be used.
- Preferred solvents are water, alcohols, nitriles, more preferably lower alkanols and/or nitriles, organic or inorganic acids.
- the electrolyte can also contain various salts, for example, as buffers.
- the electro chemical oxidation can be carried out at a temperature between 0° C. and 80° C., preferably at room temperature, by using anodes having a large oxygen overvoltage. Suitable anodes are for example gold, platinum, palladium and titanium.
- the electrolysis is preferably carried out in an electrolytic cell in which cathode and anode are separated by a diaphragm, to inhibit the admixture of the electrolyte.
- a diaphragm for example a glass filter, a ceramic plate or an ion-exchanging membrane can be used.
- the electrolysis is preferably performed with an anodic current density of 0.1 to 10 A/dm 2 .
- halogen substitution and ring closure according to the invention are completed within 5 to 10 minutes by contrast with the method described in the Belgian Pat. No. 851122, in which iodine substitution and ring closure carried out chemically take 2 to 3 hours. It has been found that for the electro chemical iodination according to the invention about 120 % of the theoretical charge is required. Halogenation may conveniently be monitored by thin layer chromatography (t.l.c.).
- the electro chemical halogenation according to the invention results in the formation of two isomers of the compounds of the formula II.
- the isomers obtained are epimers with respect to the configuration of the 6-hydrogen (exo-endo isomers), wherein reference is made to the numbering conventional in the chemistry of prostaglandins.
- the ratio of the exo epimer to the endo epimer may be varied between 1:1 to 1:10, depending on the electrolytic parameters, i. e. electrolyte concentration, quality of the anode, current density, temperature, electrolyte composition.
- the epimers obtained can be separated by column chromatography carried out on silica gel. Preferably ester derivatives of the formula II, in which R 1 represents an alkyl group are subjected to chromatography. If the compounds of the formula II are intended to be used for the preparation of prostacyclin derivatives of the formula III, the epimers generally need not be separated, since dehydrohalogenation of either of the epimers of the formula II provides the same prostacyclin
- FIG. 1 of the drawing is a diagrammatic cross section through an electrolytic cell, for carrying out the process of the invention.
- An electrolytic cell is prepared according to the setup illustrated on FIG. 1. If the reaction is to be carried out at a temperature different from room temperature, the electrolytic cell is thermostated in a conventional way. The thermostating jacket is not illustrated in the FIGURE.
- cathode 1 is dipped into the cathode space 4, while anode 2 is dipped into the anode space 5.
- the two electrode spaces are separated from each other by diaphragm 3.
- a cathode a platinum spiral having an area of 4 cm 2 , as an anode a platinum plate of 10 cm 2 is employed.
- the catholyte consists of 10 ml. of distilled water, 100 mg.
- the anolyte has the same composition as the catholyte except that it also contains 150 mg. (0.4 mmoles) of prostaglandin F 2 ⁇ .
- the anodic current density is adjusted to 6 A/dm 2 , and the electrolysis is continued at 25° C. for about 7 minutes.
- the terminal voltage is 25 V.
- the termination of the reaction is indicated by a sudden increase in the terminal voltage of the cell.
- the dark brown anolyte obtained as a result of the electrolysis is extracted with 20 ml. of ether, the ethereal extract is washed with 0.5 ml. of a 10 % sodium thiosulphate solution and subsequently with four 5 ml. portions of water, and finally dried over anhydrous magnesium sulphate, at 0° C., in darkness.
- the solution is then evaporated and acetic acid is eliminated under a pressure of 1 mmHg until a steady weight is achieved.
- As a residue 180 mg. (88 %) of 5-iodine-6,9 ⁇ -oxido-11 ⁇ ,15 ⁇ --dihydroxy-13-trans-prostenic acid are obtained. According to t.l.c.
- the product is an approximately 5:1 mixture of endo- and exo-epimers.
- T.l.c. measurements are carried out on silica gel, using a 20:10:1 mixture of benzene, dioxane and acetic acid.
- the spots obtained are identified by means of chemically pure and stereouniform 6-endo-5 ⁇ -iodine-6,9 ⁇ -oxido-11 ⁇ ,15 ⁇ -dihydroxy-13-trans-prostenic acid, prepared by a chemical method [Tetrahedron Letters 30, 2627 (1977)] which was previously identified by different methods.
- R f for the 6-endo isomer amounts to 0.25, while the 6-exo isomer has an R f -value of 0.30.
- 6-endo-5 ⁇ -iodine-6,9 ⁇ -oxido-11 ⁇ ,15 ⁇ -dihydroxy-13--trans-prostenic acid and 6-exo-isomer thereof are esterified by diazomethane in a manner known per se.
- the electrolytic cell is essentially identical with that used in Example 1, with the only difference that as an anode a platinum plate of 0.5 cm 2 area is used.
- the catholyte consists of 10 ml. of acetonitrile, 50 mg. (0.4 mmoles) of potassium bromide, 0.5 ml. of water and 0.25 ml. of acetic acid.
- the anolyte in addition to the above components contains 50 mg. (0.15 mmoles) of prostaglandin F 2 ⁇ .
- Electrolysis is performed with an anodic current density of 0.6 A/dm 2 for 20 minutes.
- the terminal voltage of the cell is of about 2 to 3 V.
- the crude product is converted into the corresponding methyl ester with diazomethane in a manner known per se.
- t.l.c. spots are identified by means of chemically pure and stereouniform corresponding endo- and exo compounds of the formula II, which had been prepared chemically [Tetrahedron Letters, 30, 2627 (1977)], and were identified by different known methods.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUCI1832 | 1978-05-29 | ||
HU78CI1832A HU179001B (en) | 1978-05-29 | 1978-05-29 | Process for preparing 5-halo-6,9alpha-oxido-prostaglandin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US4233121A true US4233121A (en) | 1980-11-11 |
Family
ID=10994698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/041,104 Expired - Lifetime US4233121A (en) | 1978-05-29 | 1979-05-21 | Process for the preparation of 5-halo-6,9 α-oxido-prostaglandin derivatives |
Country Status (9)
Country | Link |
---|---|
US (1) | US4233121A (de) |
JP (1) | JPS54163592A (de) |
AT (1) | AT374831B (de) |
DE (1) | DE2920562A1 (de) |
GB (1) | GB2027014B (de) |
GR (1) | GR68433B (de) |
HU (1) | HU179001B (de) |
IT (1) | IT1165207B (de) |
SU (1) | SU890974A3 (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4290862A (en) * | 1979-11-14 | 1981-09-22 | Edinen Centar P Chimia | Method for the preparation of narwedine-type enones |
US4510025A (en) * | 1983-08-24 | 1985-04-09 | Kuraray Company, Ltd. | Method for production of 3-substituted-2,2-dimethylbicyclo[2.2.1]heptan-5-ols and esters thereof |
AT381303B (de) * | 1981-04-14 | 1986-09-25 | Chinoin Gyogyszer Es Vegyeszet | Verfahren zur herstellung von neuen, optisch aktiven und racemischen 5-substituierten-4-oxo -pgi1-derivaten sowie von deren salzen |
AT381494B (de) * | 1981-04-14 | 1986-10-27 | Chinoin Gyogyszer Es Vegyeszet | Verfahren zur herstellung neuer 2,3,4-trinor-1,5inter-m-phenylen-prostacyclin-derivaten und von deren salzen |
AT382372B (de) * | 1982-05-06 | 1987-02-25 | Chinoin Gyogyszer Es Vegyeszet | Verfahren zur herstellung neuer 2,3,4-trinor-1,5 -inter-m-phenylen-prostacyclin-i2-analoga und von deren salzen |
US4670109A (en) * | 1985-01-25 | 1987-06-02 | Firmenich Sa | Process for the preparation of isoxazoles |
US5230783A (en) * | 1991-05-15 | 1993-07-27 | The Dow Chemical Company | Electrolytic cell and process for the labeling of proteins and peptides |
US20030181727A1 (en) * | 1999-12-17 | 2003-09-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenky | Cyanine dyes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3427235A (en) * | 1965-01-15 | 1969-02-11 | Pullman Inc | Electrolytic production of olefine oxides |
US4125712A (en) * | 1976-06-01 | 1978-11-14 | The Upjohn Company | Certain 5,6-dihydro-prostacyclin analogs |
-
1978
- 1978-05-29 HU HU78CI1832A patent/HU179001B/hu unknown
-
1979
- 1979-05-15 GR GR59087A patent/GR68433B/el unknown
- 1979-05-21 AT AT0371479A patent/AT374831B/de not_active IP Right Cessation
- 1979-05-21 DE DE19792920562 patent/DE2920562A1/de active Granted
- 1979-05-21 US US06/041,104 patent/US4233121A/en not_active Expired - Lifetime
- 1979-05-24 IT IT68106/79A patent/IT1165207B/it active
- 1979-05-25 GB GB7918487A patent/GB2027014B/en not_active Expired
- 1979-05-28 JP JP6509279A patent/JPS54163592A/ja active Granted
- 1979-05-28 SU SU792773053A patent/SU890974A3/ru active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3427235A (en) * | 1965-01-15 | 1969-02-11 | Pullman Inc | Electrolytic production of olefine oxides |
US4125712A (en) * | 1976-06-01 | 1978-11-14 | The Upjohn Company | Certain 5,6-dihydro-prostacyclin analogs |
Non-Patent Citations (4)
Title |
---|
Chem. Biochem., and Pharmacological Activity of Prostanoids, Roberts et al., p. 290, pub. by Pergamon, N.Y., 1979. * |
Intro. to Org. Electrochem, by Rifi et al., 1974, pp. 282, 298-307, pub. by Marcel Dekker, New York. * |
Mech. of Oxidation of Org. Cpds. by Waters, pp. 49-51, pub. by Methuen, London, 1964. * |
Tamoskozi et al., Tetrahedron Letters, 1977, pp. 2627, 2628. * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4290862A (en) * | 1979-11-14 | 1981-09-22 | Edinen Centar P Chimia | Method for the preparation of narwedine-type enones |
AT381303B (de) * | 1981-04-14 | 1986-09-25 | Chinoin Gyogyszer Es Vegyeszet | Verfahren zur herstellung von neuen, optisch aktiven und racemischen 5-substituierten-4-oxo -pgi1-derivaten sowie von deren salzen |
AT381494B (de) * | 1981-04-14 | 1986-10-27 | Chinoin Gyogyszer Es Vegyeszet | Verfahren zur herstellung neuer 2,3,4-trinor-1,5inter-m-phenylen-prostacyclin-derivaten und von deren salzen |
AT382372B (de) * | 1982-05-06 | 1987-02-25 | Chinoin Gyogyszer Es Vegyeszet | Verfahren zur herstellung neuer 2,3,4-trinor-1,5 -inter-m-phenylen-prostacyclin-i2-analoga und von deren salzen |
US4510025A (en) * | 1983-08-24 | 1985-04-09 | Kuraray Company, Ltd. | Method for production of 3-substituted-2,2-dimethylbicyclo[2.2.1]heptan-5-ols and esters thereof |
US4670109A (en) * | 1985-01-25 | 1987-06-02 | Firmenich Sa | Process for the preparation of isoxazoles |
US5230783A (en) * | 1991-05-15 | 1993-07-27 | The Dow Chemical Company | Electrolytic cell and process for the labeling of proteins and peptides |
US5246561A (en) * | 1991-05-15 | 1993-09-21 | The Dow Chemical Company | Electrolytic cell and process for the labeling of proteins and peptides |
US20030181727A1 (en) * | 1999-12-17 | 2003-09-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenky | Cyanine dyes |
US7402375B2 (en) | 1999-12-17 | 2008-07-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Cyanine dyes |
Also Published As
Publication number | Publication date |
---|---|
DE2920562A1 (de) | 1979-12-06 |
IT1165207B (it) | 1987-04-22 |
AT374831B (de) | 1984-06-12 |
ATA371479A (de) | 1983-10-15 |
JPS62999B2 (de) | 1987-01-10 |
IT7968106A0 (it) | 1979-05-24 |
DE2920562C2 (de) | 1989-01-19 |
GB2027014A (en) | 1980-02-13 |
HU179001B (en) | 1982-08-28 |
GB2027014B (en) | 1982-08-25 |
SU890974A3 (ru) | 1981-12-15 |
GR68433B (de) | 1981-12-30 |
JPS54163592A (en) | 1979-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Majeski et al. | Controlled potential oxidation of anthracene in acetonitrile. II | |
US4233121A (en) | Process for the preparation of 5-halo-6,9 α-oxido-prostaglandin derivatives | |
Koch et al. | Anodic chemistry of adamantyl compounds. Scissible carbon, halogen, hydrogen, and oxygen substituents | |
US5013412A (en) | Process for the electrosynthesis of a beta,gamma-unsaturated ester | |
CH633250A5 (de) | Verfahren zur herstellung von neuen polyprenylderivaten. | |
US4193850A (en) | Alkanoyloxylation of beta-ionone | |
EP0107693B1 (de) | 2,3,4-trinor-1,5-inter-m-phenylen-prostacyclin-i2-analoge, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische präparate | |
Tanaka et al. | A convenient preparation of methyl (E)-and (Z)-4, 4-dimethoxy-2-butenoates by electrolyses of furfuryl alcohol, furfural, and 2-furoic acid | |
US4290862A (en) | Method for the preparation of narwedine-type enones | |
SU1222197A3 (ru) | Способ получени бициклических соединений или стереоизомеров этих соединений или их фармацевтически приемлемых солей с кислотами | |
DE2743283A1 (de) | Neue prostacyclin-analoga | |
EP0013955B1 (de) | Neue Analoga von Prostacyclin, deren Zwischenprodukte, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel | |
AU594678B2 (en) | Electorchemical process for the preparation of organic trifluoro(or chlorodifluoro or dichlorofluoro) methyl derivatives | |
DE3442034C2 (de) | ||
US3024252A (en) | Quaternary ammonium compounds of the dihydrofurane series | |
SU671727A3 (ru) | Способ получени производных 5-нитроимидазола | |
DE3142626A1 (de) | Elektrochemisches verfahren zur herstellung von 2,5-dialkoxy-2,5-dihydrofuranen | |
US4082809A (en) | P-benzoquinone diketals | |
US4022672A (en) | Electrochemical synthesis of insecticide intermediates | |
US4475992A (en) | Cyclohexadiene derivatives and process for preparing the same | |
US4379032A (en) | Process for preparing oxazolineazetidinone derivatives | |
US4428886A (en) | Novel intermediates for the preparation of α-hydroxycarbonyl compounds | |
EP0080718B1 (de) | Inter-m-Phenylen-PGI2-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate | |
SU927117A3 (ru) | Способ получени производных гексагидробензпираноксантенонов | |
JPS61264186A (ja) | アルコ−ルおよびエポキシ化合物の電気合成方法 |